To replace animal testing with AI, we need MASSIVE human datasets. Today, we're thrilled to share Axiom's new data exploration tool, providing the ability to visually explore the world's largest primary human liver toxicity dataset. Built with Axiom's proprietary wetlab

#ASCO25 was full of practice-changing data and provocative science projects. In this essay, we've distilled four key topics that've stuck with us since. Read on.

this summer NewLimit, we built our first prototype medicine that restores multiple youthful functions in old hepatocytes. rejuvenating old cells across multiple dimensions seems more possible today than just months ago. recent highlights - +3 TF sets that restore function in

The research NewLimit over the last quarter has moved my probability that Aging is reversible to 90% and that anti-Aging Medicines will exist to 70%. Still a lot of work to do! That age is a ~plastic state continues to be the secret that the team NewLimit believes while ~the

We had an excellent time attending our first #ASCO conference this year - so much so that we decided to write up our key takeaways and open questions that we have been mulling over for the past couple weeks.

We’re excited to introduce Chai-2, a major breakthrough in molecular design. Chai-2 enables zero-shot antibody discovery in a 24-well plate, exceeding previous SOTA by >100x. Thread👇

Today, we published new discoveries in a Science Magazine cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs and our QuEEN™ discovery engine: bit.ly/4eBn8Q

Congratulations to the Monte Rosa Therapeutics, Inc team for having their work featured on the cover of Science Magazine! We (DIMENSION) are tremendously excited about the future of molecular glue degraders (MGDs) and induced proximity writ large. Even in 2025, we've only scratched the

Dimension portco Monte Rosa Therapeutics, Inc casually on the cover of Science 🚀

DIMENSION is growing our research team! join Simon Barnett & @Bauer_LeSavage as we build the premier investment firm at the interface of tech & life sciences on the planet (pictured here taking notes in Arrakis). Worm spotting skills optional .. DMs open

Come on down, this bad boy ain’t gonna turn into a green paradise by itself

Agree, this is the new status quo. Adapt or die. There’s some extremely brilliant science happening in China, combined with incredible work ethic. A rising tide floats all boats. The right response is to make domestic policy changes, galvanize discovery & development, and dial

NewLimit paper just dropped ICML Conference showing our SOTA AI models can predict perturbed cell states. Helps to have the largest primary cell perturbation dataset in the world. Bonus points for one of the first demonstration of active learning in bio.

reprogramming cells with transcription factors is our most expressive tool for engineering cell state traditionally, we found TFs by ~guesswork ICML Conference we're sharing NewLimit's SOTA AI models that can design reprogramming payloads by building on molecular foundation models

"you have to be in the water" a close analogy to beautiful chinese concept we've been playing with internally: fengkou 风口 ~ you have to be in the water to catch the best waves

great overview of DIMENSION portco NewLimit, pioneering tech in epigenetic reprogramming to ̶s̶l̶o̶w̶ reverse aging in pursuit of future life saving, life extending, medicines

Congrats to Joshua, Jack, and the stellar team at Chai Discovery!! They are doing incredible work to advance generative protein design and make biology programmable for the first time. This is just the beginning, DIMENSION is excited to continue to partner with Chai on

great to see Dimension backed axi.om and Dimension cofounded achira.ai both on Mario Gabriele 🦊's The Future 50 list below!!

Excited to introduce our newest team member, Sriram (“Rami”) Hathwar! 🚀 From winning the US Scripps National Spelling Bee, to enrolling in a Chemistry/Bio/CS curriculum at Princeton, to developing bioinformatics tools at a clinical stage biotech, Rami embodies the

i've never seen such a wide dispersion between the cutting edge & the status quo. Chai Discovery's tech (choose target(s), choose epitope(s) -> in-silico design a binder) will ultimately diffuse across the ecosystem. until then, the below is a sneak peek youtube.com/watch?v=h3aMoz…